Treace Medical Concepts, Inc.
TMCI Nasdaq· Surgical & Medical Instruments & Apparatus
Last close · Oct 23, 2026
$4.27
KIRA · Stoqly’s AI analyst, in plain words
- Treace Medical Concepts, Inc. had $213M of revenue in fiscal 2025, up 1.6% on the year before. Over five years, revenue changed +30.0% a year on average.
- Its operating margin was −25.5%, up 1.1 pts: of every 100 in sales, about −25 is left after running the business.
- Treace Medical Concepts, Inc. lost $59.0M in fiscal 2025.
- Free cash flow was −$29.5M in fiscal 2025, −13.9% of revenue.
- Treace Medical Concepts, Inc. owes $9.0M more than it holds in cash.
Market cap
$278M
P/E
—
Revenue
$213M
Net income
−$59.0M
Free cash flow
−$29.5M
Operating margin
−25.5%
Treace Medical Concepts, Inc. in 30 seconds · fiscal 2025
Are sales growing?
+1.6%
Only a little. Sales grew 1.6% last year.
Does it make a profit?
−27.7%
No. It lost money last year.
Does profit turn into cash?
−13.9%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 9
Weak. It passes 2 of 9 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Treace Medical Concepts, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 27, 2026
- Legal name
- TREACE MEDICAL CONCEPTS, INC.
- CIK
- 0001630627
Treace Medical Concepts, Inc. · TMCI
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $94.4M | $142M | $187M | $209M | $213M |
| Revenue growth | 64.6% | 50.2% | 31.9% | 11.9% | 1.6% |
| Gross margin | 82.1% | 82.0% | 81.2% | 80.4% | 79.8% |
| Operating margin | −17.5% | −24.6% | −27.5% | −26.6% | −25.5% |
| Net income | −$20.6M | −$42.8M | −$49.5M | −$55.7M | −$59.0M |
| Net margin | −21.8% | −30.2% | −26.5% | −26.6% | −27.7% |
| Diluted EPS | −$0.43 | −$0.77 | −$0.81 | −$0.90 | −$0.93 |
| Cash | |||||
| Cash from operations | −$17.2M | −$30.6M | −$34.6M | −$37.2M | −$16.0M |
| Capital expenditure | $2.7M | $14.8M | $11.5M | $11.6M | $13.5M |
| Free cash flow | −$19.9M | −$45.5M | −$46.0M | −$48.8M | −$29.5M |
| FCF margin | −21.1% | −32.1% | −24.6% | −23.3% | −13.9% |
| Share count change | 30.6% | 14.2% | 10.1% | 2.1% | 1.9% |
| Debt and strength | |||||
| Cash and short-term investments | $106M | $81.3M | $123M | $75.7M | $48.4M |
| Debt incl. finance leases | $29.4M | $52.7M | $53.0M | $53.3M | $57.3M |
| Shareholders' equity | $93.1M | $60.5M | $138M | $113M | $87.3M |
| Current ratio | 7.6x | 4.4x | 4.4x | 4.6x | 4.3x |
| Interest coverage | −4.1x | −7.9x | −10.0x | −10.6x | −10.2x |
| Returns and quality | |||||
| Return on capital | −78.5% | −86.1% | −60.0% | −48.6% | −44.4% |
| Return on equity | −43.8% | −55.7% | −49.9% | −44.4% | −58.9% |
| Return on tangible equity | −22.3% | −70.7% | −42.7% | −60.6% | −87.6% |
| Piotroski F-score | 4 | 2 | 3 | 3 | 2 |
| Altman Z'' | 5.9 | 1.7 | 2.2 | 0.4 | −1.8 |
Insiders bought, 12 months
$1.4M
1 insider
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Treace Medical Concepts, Inc. · TMCI
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.27 a share, the company is worth $278M.
Source: SEC EDGAR XBRL filings (CIK 0001630627). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.